| Document |
Document Title |
|
WO/2021/040310A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element using same.
|
|
WO/2021/039824A1 |
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...
|
|
WO/2021/031599A1 |
The present invention provides a method for preparing a drug toxin PNU-159682 (morpholinyl anthracycline derivative) of an antibody-conjugated drug, and an intermediate involved in the preparation method. According to the preparation met...
|
|
WO/2021/027566A1 |
Provided is a preparation method for an oxazepine compound, and specifically disclosed are a preparation method for a compound of formula (I) and an intermediate of same.
|
|
WO/2021/029308A1 |
The present invention addresses the problem of providing a novel insecticide for agricultural and horticultural use, the insecticide having a further reduced degree of noxiousness to humans and animals, in agricultural and horticultural ...
|
|
WO/2021/029632A1 |
The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The co...
|
|
WO/2021/028643A1 |
The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))
|
|
WO/2021/030711A1 |
The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these co...
|
|
WO/2021/026100A1 |
Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-relate...
|
|
WO/2021/024202A1 |
The present invention relates to a process for the preparation of an amorphous form of midostaurin with a low content of residual organic solvent.
|
|
WO/2021/023994A1 |
The present invention relates to a crystalline molecular complex comprising pinoxaden and a carboxylic acid. The invention also relates to a process for the preparation of the crystalline molecular complex, a herbicidal composition compr...
|
|
WO/2021/023154A1 |
Disclosed are a compound as shown in formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.
|
|
WO/2021/020363A1 |
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
|
|
WO/2021/018194A1 |
Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Fo...
|
|
WO/2021/013910A1 |
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly in plants.
|
|
WO/2021/014365A1 |
Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicam...
|
|
WO/2021/011724A1 |
Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X1 and X2 are independently C or N, provided that zero or one of X1 and X2 is N; Ring A represented by the structure is: or; and Q, R1, R2, R3, R4, R6, and p a...
|
|
WO/2021/011345A1 |
The present disclosure relates to crystalline Lorlatinib : Fumaric acid, solid state forms thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof.
|
|
WO/2021/007636A1 |
The present invention relates to the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H-
indol-3-yl)-6,7-dihydro-3H-oxazol[3,4-a]pyrazine-5,8-dione of formula (I), and also to pharmaceutically acceptable stereoisomers, ...
|
|
WO/2021/009209A1 |
Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as ...
|
|
WO/2021/011713A1 |
The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are usef...
|
|
WO/2021/010492A1 |
The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is usefu...
|
|
WO/2021/005034A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, X, and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
|
|
WO/2021/000885A1 |
A quinazoline derivative as represented by general formula (I), a preparation process therefor, a pharmaceutical composition containing the derivative and use of the derivative as a therapeutic agent, in particular as a KRAS inhibitor.
|
|
WO/2021/000935A1 |
Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 ac...
|
|
WO/2021/001328A1 |
A process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo- pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide.
|
|
WO/2020/260252A1 |
The present invention encompasses compounds of formula (I) wherein the groups R1 to R3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions w...
|
|
WO/2020/259573A1 |
A class of KRAS G12C mutant protein inhibitors, specifically disclosing the compound shown in formula (I), and an isomer and a pharmaceutically acceptable salt thereof.
|
|
WO/2020/260425A1 |
A series of substituted fused bicyclic imidazole derivatives of formula (I), including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or p...
|
|
WO/2020/264404A1 |
A composition of matter including a donor including a dithiophene unit combined with a non-fullerene acceptor. Further disclosed is a device comprising an active region including the composition of matter. Example devices include a solar...
|
|
WO/2020/261293A1 |
The present application relates to a process for the preparation of midostaurin by controlling critical impurities or by-products which in turn lead to increase in the overall yield and purity. The present application also provides midos...
|
|
WO/2020/260871A1 |
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositio...
|
|
WO/2020/257189A1 |
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer. Also provided are methods of inhibiting receptor tyrosine kinases...
|
|
WO/2020/253836A1 |
The present invention relates to a crystal form and a salt of a compound serving as a Pan-HER tyrosine kinase inhibitor and a preparation method therefor, and also use thereof in the preparation of a medicament for treating solid tumors.
|
|
WO/2020/257271A1 |
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I) where A, B, R1, X1, X2, and W are described h...
|
|
WO/2020/257165A1 |
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
|
|
WO/2020/255004A1 |
The present invention generally relates to polymorphic forms of bictegravir, its salts, co-crystals, solvates or hydrates thereof and process for the preparation of the same and also relates to pharmaceutical compositions containing the ...
|
|
WO/2020/257043A1 |
The embodiments of present invention provide processes and intermediates for the preparation of D1 PAM I: Formula (I).
|
|
WO/2020/257253A1 |
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I) where A1, A2, G, R1, R2, R3, R4, and W are de...
|
|
WO/2020/255022A1 |
Therapeutic combinations of hepatitis B virus (HBV) vaccines and HPK1 inhibitors are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infecti...
|
|
WO/2020/257169A1 |
This disclosure relates to polymorphs of (3aR,11S,20aS)-7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro
-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyra
zolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(
11H)-one that...
|
|
WO/2020/253659A1 |
Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2020/249079A1 |
A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase alloster...
|
|
WO/2020/249970A1 |
The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associa...
|
|
WO/2020/248065A1 |
The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemic...
|
|
WO/2020/249969A1 |
The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorder...
|
|
WO/2020/251953A1 |
Disclosed herein, inter alia, are streptogramin compounds, compositions, and methods of use thereof. A method of treating an infectious disease, the method including administering to a subject in need thereof an effective amount of a com...
|
|
WO/2020/252222A1 |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).
|
|
WO/2020/246910A1 |
The present invention relates to a novel compound that exhibits antiviral activity, and more particularly inhibitory activity toward the integrase of the human immunodeficiency virus (HIV). The subject matter of the present invention is ...
|
|
WO/2020/247160A1 |
The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautom...
|
